CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 870 target
Drug / intervention
Cilostazol 100 MG +1 moredrug
Likely dose
Cilostazol 100 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06591299
NCT06591299Phase 3RecruitingUpdate OverdueUpdated 21mo ago · Completion was 21mo ago
Enrollment Stalled
Long Recruiting
Update Overdue

Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA, a Randomized Controlled Trial

Kafrelsheikh University·interventional·Posted Sep 19, 2024·Updated Sep 19, 2024

In Brief

A Phase 3 clinical trial evaluating Cilostazol 100 MG and Clopidogrel 75mg for Ischemic Stroke. Currently recruiting, targeting 870 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of clopidogrel administered within 24 hours of the first-ever minor stroke or TIA compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesEgypt
Collaborators--

Timeline

Phase 3RecruitingOverdue
2023202420252026
First PostedSep 19, 2024
Enrollment StartApr 15, 2022
Primary CompletionSep 15, 2024
Study CompletionSep 30, 2024
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 1.8 years ago

Interventions

Cilostazol 100 MGdrug

Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,

Clopidogrel 75mgdrug

Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,